FDA provides useful Orange Book update for generics drugmakers

The US Food and Drug Administration has started including patent submission dates in the so-called Orange Book, the record of approved drug products.

The agency says it will include this data to improve transparency and provide additional information to regulated industry and the public.

It will also help generic drug manufacturers to determine the earliest date when they may be able to market new generic medicines.